AMA Urges HHS to Withdraw Policy Allowing Unapproved Peptides

Share

The American Medical Association is urging HHS to rescind a proposed enforcement discretion policy that would permit pharmacies and physicians to compound six unapproved peptides, warning that the policy could expose patients to substances that have not undergone FDA reviews for safety, effectiveness or quality.

In a recent letter to HHS, the AMA opposed the department's plan to exercise enforcement discretion for compounding BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon while FDA considers whether to add the substances to the Section 503A bulk drug substances list.

The policy, announced 10/30, would allow qualifying state-licensed pharmacies, federal facilities and licensed physicians to compound the peptides without facing certain federal enforcement actions, subject to specified conditions. It would not constitute FDA approval.

The AMA said FDA previously excluded the substances from the 503A Bulks List and that none is currently being studied under an active IND.

The association warned that the policy could expose patients to products with uncertain identity, purity, potency, dosing and safety, potentially resulting in allergic reactions, infections, hormonal imbalances and other adverse effects.

"We should not bypass the science and put patients at risk by making them guinea pigs for unapproved drugs," AMA president Willie Underwood III said in a 11/18 statement.

HHS has said the policy is intended to expand patient access to peptides for which approved alternatives are unavailable. The department also said it could reconsider the policy if safety signals or product quality problems emerge.

The AMA urged HHS to require adequate clinical testing and FDA review before expanding access to the substances. The association also recently adopted a policy calling for stronger enforcement against the distribution of unapproved synthetic peptides by compounding pharmacies, telehealth platforms and online dispensaries.

Read more